Patents Assigned to Parker Hughes Institute
  • Vanadium (IV) metallocene complexes having spermicidal activity
    Patent number: 6500860
    Abstract: Novel spermicidal compounds which are organometallic cyclopentadienyl metal complexes, particularly vanadium IV complexes, are described including corresponding contraceptive and therapeutic compositions and method for providing contraception and selective killing of testicular germ cells. Included among the vanadium complexes are bis(methyl cyclopentadienyl)vanadium dichloride, vanadocene di-pseudohalides, and others. Most active found was vanadocene diselenocyanate.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: December 31, 2002
    Assignee: Parker Hughes Institute
    Inventors: Osmond D'Cruz, Phalguni Ghosh, Fatih M. Uckun
  • Use of EGF genistein to prevent development of EGF-receptor expressing cancers
    Publication number: 20020193319
    Abstract: The invention provides a method for preventing the development or recurrence of cancer in a mammal by administering to the mammal a compound comprising an isoflavone, such as Genistein, conjugated to epidermal growth factor (EGF).
    Type: Application
    Filed: May 14, 2002
    Publication date: December 19, 2002
    Applicant: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • Dimethoxy quinazolines for treating diabetes
    Patent number: 6495556
    Abstract: The invention provides novel JAK-3 inhibitors that are useful for treating leukemia and lymphoma. The compounds are also useful to treat or prevent skin cancer, as well as sunburn and UVB-induced skin inflammation. In addition, the compounds of the present invention prevent the immunosuppressive effects of UVB radiation, and are useful to treat or prevent autoimmune diseases, inflammation, and transplant rejection. The invention also provides pharmaceutical compositions comprising compounds of the invention, as well as therapeutic methods for their use.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: December 17, 2002
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Elise A. Sudbeck, Marina Cetkovic, Ravi Malaviya, Xing-Ping Liu
  • Syk localized at centrosome
    Publication number: 20020187506
    Abstract: The method of the invention includes use of Syk, Syk-conjugte, Syk-binding ligand, or Syk inhibitor as a marker for the analysis of a cell's centrosome, centrioles, or mitiotic spindle, for example, in the diagnosis of cellular proliferation disorders, or for the study of cell cycle. In addition, the method of the invention included use of Syk-binding ligand or Syk inhibitors to inhibit the function of centrosome, centrioles, or mitiotic spindle, for example in the inhibition of cell proliferation, particularly cancer.
    Type: Application
    Filed: May 29, 2002
    Publication date: December 12, 2002
    Applicant: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • 4-(4'-HYDROXYPHENYL) AMINO-6,7-DIMETHOXYQUINAZOLINE TO PREVENT DEVELOPMENT OF COLORECTAL CANCER
    Publication number: 20020183340
    Abstract: The present invention is directed to a method of preventing the development or recurrence of colorectal cancer in a mammal comprising adminstering to the mammal an effective cancer preventive amount of 4(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 14, 2002
    Publication date: December 5, 2002
    Applicant: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • AZT derivatives exhibiting spermicidal and anti-viral activity
    Patent number: 6482805
    Abstract: Contraceptive activity as well as anti-viral protection can be provided by contraceptive compositions containing a pyrimidine-based nucleoside or nucleotide exhibiting spermicidal or sperm-immobilizing activity. In one example, the active ingredient contains a thymine ring (e.g. AZT) that has 5-halo, 6-alkoxy substitution. Additional improvements in anti-HIV activity for certain AZT derivatives are seen by providing the pentose ring of AZT with aryl phosphate substitution.
    Type: Grant
    Filed: December 1, 2000
    Date of Patent: November 19, 2002
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Osmond D'Cruz, Taracad Venkatachalam
  • Organic arsenic compounds
    Patent number: 6482816
    Abstract: Novel organic arsenic compounds are described as cytotoxic agents with potent anti-tumor activity against cancer cells and particularly, with regard to human leukemic cells and breast cancer cells.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: November 19, 2002
    Assignee: Parker Hughes Institute
    Inventors: Faith M. Uckun, Xing-Ping Liu
  • 4-(4?-hydroxyphenyl) amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer
    Patent number: 6482828
    Abstract: The present invention is directed to a method of preventing the development or recurrence of colorectal cancer in a mammal comprising administering to the mammal, an effective cancer preventative amount of 4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: November 19, 2002
    Assignee: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • Organic-arsenic compounds
    Patent number: 6482815
    Abstract: Novel organic arsenic compounds are described as cytotoxic agents with potent anti-tumor activity against cancer cells and particularly, with regard to human leukemic cells and breast cancer cells.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: November 19, 2002
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Xing-Ping Liu
  • Inhibiting collagen-induced platelet aggregation
    Publication number: 20020169207
    Abstract: The present invention describes a therapeutic method useful for treating or preventing a condition of platelet aggregation in a subject including administering to the subject a pharmaceutically effective amount of a compound or composition that inhibits BTK and collagen-induced platelet aggregation. The condition of platelet aggregation includes cardiovascular, hematopoietic and cerebrovascular diseases.
    Type: Application
    Filed: February 15, 2002
    Publication date: November 14, 2002
    Applicant: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • JAK-3 inhibitors for treating allergic disorders
    Publication number: 20020165243
    Abstract: Inhibitors of JAK3 kinase for the treatment of allergy, and others are described.
    Type: Application
    Filed: April 23, 2002
    Publication date: November 7, 2002
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Ravi Malaviya, Elise A. Sudbeck
  • Quinazolines for treating brain tumor
    Publication number: 20020161226
    Abstract: Novel substituted quinozaline compounds and conjugates useful to inhibit the growth of brain tumor cells and to inhibit adhesion and migration of brain tumor cells. The compounds of the invention include 4-(3′-bromo-4′-hydroxy phenyl)-amino-6,7-dimethoxyquinazoline and this compound covalently bound to EGF.
    Type: Application
    Filed: July 11, 2001
    Publication date: October 31, 2002
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Rama Krishna Narla, Xing-Ping Liu
  • Therapeutic compounds
    Patent number: 6469013
    Abstract: The invention provides novel JAK-3 inhibitors that are useful for treating leukemia and lymphoma. The compounds are also useful to treat or prevent skin cancer, as well as sunburn and UVB-induced skin inflammation. In addition, the compounds of the present invention prevent the immunosuppressive effects of UVB radiation, and are useful to treat or prevent autoimmune diseases, inflammation, and transplant rejection. The invention also provides pharmaceutical compositions comprising compounds of the invention, as well as therapeutic methods for their use.
    Type: Grant
    Filed: May 16, 2001
    Date of Patent: October 22, 2002
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Elise A. Sudbeck, Marina Cetkovic, Ravi Malaviya, Xing-Ping Liu
  • Cyclohexenyl-ethyl-thiourea compounds for inhibiting HIV reverse transcriptase
    Patent number: 6469034
    Abstract: Novel CycloHexenyl-Ethyl-Thiourea (CHET) compounds as inhibitors of reverse transcriptase and effective agents for the treatment of HIV infection, including mutant, drug-sensitive, drug-resistant, and multi-drug resistant strains of HIV.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: October 22, 2002
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Taracad K. Ventatachalam
  • Synthetic spiroketal pyranes as potent anti-cancer agents and use
    Publication number: 20020151580
    Abstract: Novel tubulin binding compounds (SPIKETS) having potent tubulin depolymerization activity and inhibitory activity against tubulin polymerization. The compounds are effective agents for inhibiting cellular proliferation, for example, in cancer cells. The compounds are adapted to interact favorably with a novel SP binding pocket on tubulin, which pocket is useful for screening of anti-tubulin, anti-proliferation, and anti-cancer drugs.
    Type: Application
    Filed: October 9, 2001
    Publication date: October 17, 2002
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Chen Mao, He Huang
  • One pot synthesis of 5?-hydroxy phosphorylated nucleoside derivatives, and compounds formed thereby
    Patent number: 6465641
    Abstract: A method for the preparation of 5′-hydroxy phosphorylated nucleoside derivatives in a single reaction vessel is provided. The method includes contacting phosphorous oxychloride with a halophenyl moiety followed by contacting the resulting halophenylphosphorodichloridate with a carboxy-protected amino acid and finally contacting the resulting halophenyl carboxy-protected amino acid phosphorochloridate with a nucleoside.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: October 15, 2002
    Assignee: Parker Hughes Institute
    Inventors: Shyi-Tai Jan, Fatih M. Uckun
  • Vanadium (IV) complexes containing catecholate ligand and having spermicidal activity
    Patent number: 6465450
    Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: October 15, 2002
    Assignee: Parker Hughes Institute
    Inventors: Phalguni Ghosh, Fatih M. Uckun, Osmond D'Cruz
  • Quinazolines and therapeutic use thereof
    Publication number: 20020137757
    Abstract: Quinazoline compounds and methods for the treatment of cancer and for the treatment of allergic reactions.
    Type: Application
    Filed: August 7, 2001
    Publication date: September 26, 2002
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Xing-Ping Liu, Rama Krishna Narla
  • JAK-3 inhibitors for treating allergic disorders
    Patent number: 6452005
    Abstract: Inhibitors of JAK3 kinase for the treatment of allergy inhibit mast cell degranulation an dmediator release.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: September 17, 2002
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Ravi Malaviya, Elise A. Sudbeck
  • Quinazoline formulations and therapeutic use thereof
    Publication number: 20020111360
    Abstract: Pharmaceutical compositions for parenteral administration of poorly soluble quinazoline compounds in the form of microemulsions or micellar solutions are described. The compositions are useful in treating patients suffering from cancer or having allergic reactions.
    Type: Application
    Filed: September 19, 2001
    Publication date: August 15, 2002
    Applicant: PARKER HUGHES INSTITUTE
    Inventors: Seang H. Yiv, Mingshu Li, Fatih M. Uckun